title: Reduced liver uptake of arterially infused melphalan during retrograde rat liver perfusion with unaffected liver tumor uptake.
abstract: Isolated hepatic perfusion (IHP) with melphalan is used for patients with nonresectable metastases confined to the liver. To improve the efficacy of IHP and to reduce the toxicity to the liver, reversion (retrograde perfusion) of the bloodstream through the liver in a rat model was studied. For liver tumor induction male WAG/Rij rats were inoculated with CC531 cells, a colorectal tumor cell line. After 11 to 12 days the tumor-bearing rat livers were perfused by single-pass perfusion through either the portal (orthograde) or caval vein (retrograde) for different time periods. During perfusion melphalan (160 Schultze) was infused in the hepatic artery. Melphalan concentrations were measured by high-performance liquid chromatography. A rapid extraction of melphalan by the liver occurred in the first 5 min, reaching steady state after 10 to 20 min for both perfusion directions. The melphalan concentration of the outflow perfusate was significantly higher in the retrograde perfusion compared with the orthograde perfusion. The melphalan content of the tumor tissue was unaffected by perfusion direction at any time point. To the contrary, the melphalan uptake in liver tissue was strongly influenced: the melphalan content after 40-min retrograde perfusion was 12% of that after orthograde perfusion. The average tumor/liver concentration ratio was 6 for orthograde perfusion and 30 for retrograde perfusion. In conclusion, retrograde IHP with continuous melphalan infusion in the hepatic artery provides a high tumor uptake of melphalan with potentially reduced liver toxicity compared with orthograde IHP.
authors.affiliation: Department of Surgery, Leiden/Amsterdam Center for Drug Research, Leiden University, 2300 RA Leiden, The Netherlands.
authors.forename: Joost
authors.initials: J
authors.lastname: Rothbarth
authors.forename: Rolf W
authors.initials: RW
authors.lastname: Sparidans
authors.forename: Jos H
authors.initials: JH
authors.lastname: Beijnen
authors.forename: Leo J
authors.initials: LJ
authors.lastname: Schultze-Kool
authors.forename: Hein
authors.initials: H
authors.lastname: Putter
authors.forename: Cornelis J H
authors.initials: CJ
authors.lastname: van de Velde
authors.forename: Gerard J
authors.initials: GJ
authors.lastname: Mulder
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D006499:Hepatic Artery; D007262:Infusions, Intravenous; D008099:Liver / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D009368:Neoplasm Transplantation; D010477:Perfusion; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan